Table 2. Demographic data of the pathology confirmed cohort.

	PSP	CBD	MSA-P	PD	FTLD-bvFTD
N	206	54	51	53	73
Age at onset	66.2 ± 0.6 [41-91]	63.3 ± 1.3* [42-81]	59.3 ± 1.3*** [40-80]	58.8 ± 1.5*** [40-80]	57.1 ± 1.0*** [35-74]
Age at death	74.0 ± 0.6 [54-94]	69.8 ± 1.2** [49-85]	66.8 ± 1.2*** [51-90]	73.1 ± 1.2 [56-90]	63.8 ± 1.2*** [41-84]
Disease duration	7.9 ± 0.3 [2-27]	6.8 ± 0.4 [3-12]	7.2 ± 0.4 [2-15]	14.6 ± 1.0*** [3-34]	6.7 ± 0.5 [1-20]

Demographic data of definite PSP, CBD, MSA, PD, and FTD patients. Data are mean ± SD [range]. ANOVA followed by post hoc LSD test:

^*P<0.05,

^**P<0.01,

^***P<0.001, vs. PSP.

Abbreviations: PSP, progressive supranuclear palsy; CBD, corticobasal degeneration; MSA-P, multiple system atrophy with predominant parkinsonism; PD, Parkinson's disease; FTLD, frontotemporal lobar degeneration; bvFTD, behavioral variant of frontotemporal dementia.